Drug Type Monoclonal antibody |
Synonyms STSA 1005, STSA-1005 |
Target |
Mechanism CSF-2R antagonists(Granulocyte-macrophage colony-stimulating factor receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 1 | US | 11 Aug 2022 |